Our results also demonstrated a consistent, but modest, sensitivity of p190-cell lines to IFNα treatment alone, and it was further enhanced with imatinib combination treatment, which could be an attractive treatment option for further investigation in high-risk p190-CML patients. This evidence concerns the gene CNTNAP1 and chronic myelogenous leukemia, BCR-ABL1 positive.